NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

The 10-K number (450–500 patients/year) refers to a theoretical anticipated capacity of the two B-suites at Sawston. That figure has never been demonstrated in practice, never been confirmed in any MHRA inspection summary, and never been updated in any subsequent filing. So treating it as a hard, operational number is misleading at best.

What is factual:
NWBO anticipated 40–45 patients/month in manual Grade B mode, years ago.
That estimate pre-dates Advent acquisition, Flaskworks integration, and the C-lab redesign.
The company has never stated they achieved, sustained, or even approached that throughput.

What is not factual:
Taking that old theoretical manual capacity and magically doubling it to “~1000 patients per year” by assuming a Grade C lab will automatically add the same output.

NWBO has never disclosed:
throughput per Flaskworks unit
number of units planned
staffing model
cycle times
QA/QC timing
release testing constraints
actual MHRA-cleared capacity for C-grade automation

So the “1000 per year” narrative isn’t based on evidence. It’s just stacking one theoretical estimate on top of another and calling it capacity math and that is what I was saying in the post you responded to.

The only concrete points we have are:
Two Grade B suites exist.
Their anticipated manual capacity was published years ago, but never validated publicly.
A Grade C expansion is in progress, but no capacity numbers exist.
Flaskworks/Eden is the intended scale-up pathway, not manual.
Everything beyond that is speculation dressed up as operational fact.